GlassScriptPhysician profile
Allyson E Mills
NPI 1811398829
$5,482.74
in general payments reported to CMS, 2019-2025
26 companies · $947 in 2025
The $947 reported for 2025 was more than what 87% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $527 · 2022: $1,421 · 2023: $1,296 · 2024: $1,292 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,436 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,436.26 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,334.79 | 2021-2025 | |
| Amgen INC. | $1,233.06 | 2021-2025 | Enbrel, Tavneos, Otezla |
| Janssen Biotech, INC. | $542.76 | 2022-2025 | Tremfya |
| Ucb, INC. | $500.71 | 2021-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $393.59 | 2021-2025 | |
| Pfizer INC. | $336.71 | 2021-2025 | |
| Lilly USA, LLC | $291.62 | 2022-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $227.19 | 2021-2025 | Orencia |
| Sandoz INC. | $95.52 | 2023-2025 | Hyrimoz |
| Astrazeneca Pharmaceuticals LP | $75.60 | 2022-2024 | Saphnelo |
| Organon LLC | $67.45 | 2023-2025 | Hadlima, Renflexis, Nexplanon |
| Radius Health, INC. | $59.56 | 2025 | Tymlos |
| Mallinckrodt Hospital Products INC. | $56.15 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.67 | 2023-2024 | Cyltezo |
| Genentech USA, INC. | $26.10 | 2025 | Actemra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $25.12 | 2025 | |
| Abbott Laboratories | $24.55 | 2025 | Esprit |
| Sobi, INC | $23.53 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $21.67 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $19.26 | 2024 | Crysvita |
| Fresenius Kabi USA, LLC | $17.28 | 2023 | Idacio |
| Kyowa Kirin, INC. | $17.10 | 2023 | |
| Horizon Therapeutics Plc | $17.03 | 2021 | |
| Celgene Corporation | $16.32 | 2021 | |
| Genzyme Corporation | $14.66 | 2023 | |
| Alexion Pharmaceuticals, INC. | $13.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.